PureTech Health (PRTC) investor relations material

Business model and strategy

• Operates a hub-and-spoke biopharmaceutical model, spinning out companies to advance drug assets.

• Focuses on assets with proven human pharmacology, often repurposing or improving shelved drugs.

• Achieved three FDA approvals, including a novel schizophrenia treatment, and leverages external capital for spin-outs.

• Maintains significant equity and non-dilutive economics (milestones, royalties) in spun-out entities.

• Self-funded for nearly eight years, with $320 million in cash and no near-term capital needs.

Pipeline and clinical progress

• Celea Therapeutics is advancing deupirfenidone for IPF, with successful phase 2b data and a phase 3 trial planned for the first half of the year.

• Gallop Oncology is developing LYT-200 for AML and high-risk MDS, with phase 1 results expected soon.

• Seaport Therapeutics, spun out and externally funded, uses the Glyph platform for lymphatic drug delivery and holds two clinical-stage assets.

• Ongoing internal innovation hub is developing new assets, with future programs to be revealed as they mature.

Clinical trial design and differentiation

• Deupirfenidone phase 3 will be a 52-week, head-to-head superiority study versus pirfenidone, focusing on FVC as the primary endpoint.

• Phase 2 showed a 50% greater effect size for deupirfenidone over pirfenidone, with favorable GI tolerability.

• Superiority design chosen for regulatory clarity and market differentiation, aiming for statistical significance (p < 0.05).

• Deuterium substitution in deupirfenidone allows higher exposure with acceptable tolerability, potentially improving efficacy and patient adherence.